Safety of Prophyla
Safety of Prophylactic Intracameral Moxifloxacin during Phacoemulsification
Sherif A. K. Amer1, Mohamed Y. Sayed Saif1, Ahmed T. Sayed Saif2, Passant S. Saif3
1 Department of Ophthalmology, Beni Sueif University, Egypt.
2 Department of Ophthalmology, Fayoum University, Egypt.
3 Department of Ophthalmology, Misr University for Science and technology, Egypt.
Abstract: Aim of the work: To evaluate the safety of Intracameral moxifloxacin during standard coaxial phacoemulsification .Subjects and Methods: a prospective randomized controlled clinical trial. Sixty patients with 60 eyes were divided into two Groups: Group, 1: Vigamox group ( 30 eyes), Group 2: Control group ( 30 eyes) Injection of 0.1cc Moxifloxacin using insulin 30G syringe in group 1were done at the end of Standard coaxial phacoemulsification with Foldable IOL. Results The mean age was 64.2 ± 7.8 years. The preoperative VA range from HM to 6/12 which changed postoperatively as mostly improved more than 6/18 with a total lines gained up to 12 lines. The intraoperative complications, were few in which 4 eyes showed posterior capsular dehiscence, 1 eye with Positive Vitreous Pressure (3.3%) & one case of Vitreous Prolapse (3.3%). Post-operative complications was corneal edema which was slightly more in vigamox group than that occurring in the control group, corneal edema occurred in 8 cases in the vigamox group and 6 cases in the control group, 5 cases suffered from Suture-Induced Astigmatism. Unfortunately there was one case suffered from endophthalmitis, one with Pupillary Block, one with Retained Lens Material, one case of media opacity, also one case with Shallow Anterior Chamber. The average endothelial cell density in the control group was 2366.75 and changed to 2083.75.While the average endothelial cell density in the vigamox group was 2533.21 then one month postoperatively changed to 2006.29 meaning that there was a decrease of 283 in the control group compared to the 526.93 decrease in the vigamox group. Conclusion: Intracameral 0.1 ml of 0.5% moxifloxacin (Vigamox, Alcon) was found to be safe for the visual rehabilitation and corneal endothelium,. Use of Intracameral moxifloxacin can be a beneficial adjunct to topical dosing for surgical prophylaxis.
[Sherif A. K. Amer, Mohamed Y. Sayed Saif, Ahmed T. Sayed Saif, Passant S. Saif. Safety of Prophylactic Intracameral Moxifloxacin during Phacoemulsification. J Am Sci 2013;9(6):14-27]. (ISSN: 1545-1003).http://www.jofamericanscience.org. 3
Key words: Intracameral Moxifloxacin, vigamox, endophthalmitis. Full Text 3